Accessibility Menu
Eom Pharmaceuticals logo

Eom Pharmaceuticals(OTC) IMUC

Market Cap$29.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-54%
5 Year-50%
1 Year+136%
1 Month-13%
$0.23
+80.55%
+0.10Today
Eom Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.232026-07-31
Eom Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+12.52%USD 0.212026-07-24
1 month-12.97%USD 0.272026-06-30
3 month+175.7%USD 0.092026-05-01
Year to date+230.85%USD 0.072025-12-31
1 year+135.61%USD 0.102025-07-30
3 year-37.86%USD 0.382023-08-01
5 year-50.02%USD 0.472021-07-30
Since inception-53.94%USD 0.512021-12-03

Eom Pharmaceuticals Financials at a Glance

Market Cap

$29.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.65M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.04 (Low)

Price

$0.23

Volume

10

Open

$0.13

Previous Close

$0.23

Daily Range

$0.13 - $0.23

52-Week Range

$0.04 - $0.34

Estimated Earnings Date

N/A

IMUC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eom Pharmaceuticals

EOM Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative medications that have the potential to transform existing therapeutic approaches. The company is headquartered in Montvale, New Jersey, and is actively working on key drug candidates, including EOM613 and EOM147.

Products and Services
  • Development of innovative biopharmaceutical treatments
  • Focus on clinical-stage drug candidates EOM613 and EOM147
  • Research aimed at revolutionizing therapeutic approaches
Growth Outlook
  • Strong pipeline with multiple drug candidates in development
  • Potential for significant market impact in the biotechnology sector
  • Commitment to advancing innovative therapies for unmet medical needs
Financial Highlights
  • Recent quarterly net income of -$464,525, showing ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $0, indicating a focus on development
  • Cash and cash equivalents of $613,244 as of Q4 2022, supporting ongoing operations
EOM Pharmaceuticals Holdings, Inc. operates in the biotechnology industry, emphasizing the development of groundbreaking treatments. The company is currently in the clinical stage, which is a critical phase for drug development. The focus on innovative therapies positions EOM Pharmaceuticals to potentially address significant gaps in current medical treatments. The growth outlook remains promising, with a robust pipeline of drug candidates that could lead to substantial advancements in healthcare. Financially, the company is in a phase of investment, as indicated by the recent net income figures, which reflect ongoing research and development efforts. The cash reserves provide a foundation for sustaining operations while pursuing these ambitious goals. Overall, EOM Pharmaceuticals Holdings, Inc. represents a unique opportunity within the biotechnology sector, driven by a commitment to innovation and addressing unmet medical needs.
AI Generated • Jul 6, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Irach B. Taraporewala, PhD

Website

www.eompharma.com

Headquarters

Montvale, NJ 07645, US

IMUC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

127.66%

Return on Capital

N/A

Return on Assets

-1933.07%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$29.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

126.50M

Volume

10

Avg. Volume

7.60K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$2.89M

EBITDA

-$2.29M

Operating Cash Flow

-$689.34K

Capital Expenditure

$0.00

Free Cash Flow

-$689.34K

Cash & ST Invst.

$613.24K

Total Debt

$3.47M

Eom Pharmaceuticals Performance Analysis

Eom Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Eom Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-31N/A
Q22022-06-30N/A
Q32022-09-30N/A
Q42022-12-31N/A
Eom Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.02-60.3%
20232023-12-31USD -0.02-35.0%
20242024-12-31USD -0.027.9%
20252025-12-31USD -0.02-7.3%
Eom Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-03-3190.6%
Q22022-06-3018.8%
Q32022-09-30-19.6%
Q42022-12-3138.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$29.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.91M

N/A

Employees

3

N/A

Net Income

-$464.53K

-15671.9%

EBITDA

-$315.40K

N/A

Quarterly Fundamentals

Name
Q4 2022YOY CHG

Total Cash

$613.24K

+4897.5%

Total Debt

$3.47M

+188.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$619.94K

-48.4%

Short Term Debt

$2.85M

N/A

Return on Assets

-19.33%

N/A

Return on Invested Capital

1.70%

N/A

Free Cash Flow

-$687.93K

N/A

Operating Cash Flow

-$687.93K

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DVHGFDevonian Health Group Inc.
$7.00+0.00%
LVCLFAlgorae Pharmaceuticals Limited
$0.01+0.00%
PRVCFPreveCeutical Medical Inc.
$0.01-48.62%
NYMXFNymox Pharmaceutical Corporation
$0.02+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About IMUC

What is the current price of Eom Pharmaceuticals?

Eom Pharmaceuticals is trading at $0.23 per share.

What is the 52-week range for Eom Pharmaceuticals?

Over the past 52 weeks, Eom Pharmaceuticals has traded between $0.04 and $0.34.

How much debt does Eom Pharmaceuticals have?

As of the most recent reporting period, Eom Pharmaceuticals reported total debt of $1.76M.

How much cash does Eom Pharmaceuticals have on hand?

Eom Pharmaceuticals reported $29.76K in cash and cash equivalents in its most recent financial results.

What is Eom Pharmaceuticals’s dividend yield?

Eom Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services